Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  20.00 13.61% 167.00 12,288,457 16:35:11
Bid Price Offer Price High Price Low Price Open Price
166.00 166.80 174.90 161.60 162.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -17.73 -9.46 336
Last Trade Time Trade Type Trade Size Trade Price Currency
18:39:45 O 31,389 167.00 GBX

Synairgen (SNG) Latest News (3)

More Synairgen News
Synairgen Investors    Synairgen Takeover Rumours

Synairgen (SNG) Discussions and Chat

Synairgen Forums and Chat

Date Time Title Posts
21/10/202100:32SNG001; a potential treatment for Covid 1955,913
20/10/202123:58SNG Blip in the Matrix is due 44.44532
20/10/202122:15Synairgen - a potential cure for Covid 19?20,412
14/10/202120:53To Nobby-
11/10/202101:11Bullshit free zone187

Add a New Thread

Synairgen (SNG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-10-20 16:14:56166.1798,417163,535.59O
2021-10-20 16:14:01166.1797,914162,699.78O
2021-10-20 16:13:57167.614,0146,727.74O
2021-10-20 16:13:15167.591,6272,726.64O
2021-10-20 16:12:31166.1797,914162,699.78O
View all Synairgen trades in real-time

Synairgen (SNG) Top Chat Posts

Synairgen Daily Update: Synairgen Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 147p.
Synairgen Plc has a 4 week average price of 121p and a 12 week average price of 121p.
The 1 year high share price is 199p while the 1 year low share price is currently 75p.
There are currently 201,341,825 shares in issue and the average daily traded volume is 1,102,707 shares. The market capitalisation of Synairgen Plc is £336,240,847.75.
blakieboy7: Zak Mir comments - Phase 3 is normally a big deal in the world of biotech / pharma. This is what Synairgen (SNG), the respiratory company has just achieved, on news that the external data safety monitoring board (DSMB) of the ACTIV-2 study has recommended that SNG001 advance into Phase 3 in mild to moderate COVID-19 patients. The company said that the advancement of SNG001 from Phase 2 to Phase 3 of the large ACTIV-2 trial is very welcome news and continues to build the case that its formulation of inhaled IFN-beta may have an important role in combatting COVID-19 and future emerging virus threats.
blakieboy7: RNS Number : 5946PSynairgen plc20 October 2021Synairgen plc('Synairgen' or the 'Company')Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsoredACTIV-2 COVID-19 TrialSouthampton, UK - 20 October 2021: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum anti-viral protein interferon beta (IFN-beta) for the treatment of severe viral lung infections, has been informed that the external data safety monitoring board (DSMB) of the ACTIV-2 study has recommended that SNG001 advance into Phase 3 in mild to moderate COVID-19 patients.Phillip Monk, Chief Scientific Officer of Synairgen, explained : "Interferon beta is a naturally-occurring protein, which orchestrates the body's antiviral responses. SARS-CoV-2 suppresses IFN-beta production to compromise the immune system; the aim of delivering SNG001 directly into the lungs is to restore or boost natural antiviral defences to prevent the virus from causing severe lower respiratory tract illness. Unfortunately, despite vaccination programmes and early interventions, thousands of patients are still hospitalised every day due to COVID-19-induced breathing difficulties. Data to date suggests SNG001 is well tolerated with a favourable safety profile and there is growing evidence to support the rationale for delivering IFN-beta directly into the lungs to counter the effects of SARS-CoV-2."Richard Marsden, CEO of Synairgen, said: "The advancement of SNG001 from Phase 2 to Phase 3 of the large ACTIV-2 trial is very welcome news and continues to build the case that our formulation of inhaled IFN-beta may have an important role in combatting COVID-19 and future emerging virus threats. In addition to the ACTIV-2 trial, our own Phase III SPRINTER study assessing SNG001 in hospitalised COVID-19 patients, is also progressing well and we expect top-line results in early 2022."As of today, Synairgen has not received any data from the ACTIV-2 trial.Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is a public-private partnership to develop a coordinated research strategy to accelerate the development of the most promising COVID-19 treatments and vaccines. ACTIV-2 is testing agents in non-hospitalised adults experiencing mild to moderate COVID-19 and is sponsored by NIAID, part of the National Institutes of Health, and is led by the NIAID-funded AIDS Clinical Trials Group (ACTG). To read more about ACTIV-2, visit their website here .This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014 ('MAR').For further enquiries, please contact
narc1: News flash : infamous loser BR states sng share price will be less than £1 on Monday. Jaaaaaahaaaahhhaaa
nortic 007: Synairgen (Buy, TP: 990p) Strong progress in H1, major catalysts approaching Synairgen has made strong clinical and operational progress in H1. Recruitment in the Phase 3 trial has accelerated in recent months, and is also now enrolling vaccinated patients suffering severe breakthrough infections. The US ACTIV-2 out-patient trial also appears poised to commence Phase 3, which points to success in Phase 2. We have previously highlighted waning vaccine efficacy in Israel and now note similar trends in the UK and US. Effective treatments remain urgently needed, and we continue to believe SNG001 is one of the most promising broad spectrum anti-virals, that unlike vaccines and monoclonal antibodies is unlikely to place evolutionary pressure on the virus. We also think SNG001 has potential for future pandemic preparedness (stock-piling) and for seasonal respiratory threats (influenza, rhinovirus, RSV and coronaviruses) and now await Phase 3 data in early 2022. Our risk/reward Buy case remains unchanged and our risked, base case valuation continues to support our 990p price target with a £50 per share Bull case (take-out valuation) if SNG001 delivers as we expect. Download Strong progress in H1, major catalysts approaching (4 pages) H1 results: Synairgen significantly increased R&D investment (£37m) in H1 following the start of the global Phase 3 study earlier in the year. The loss before tax of £39m includes a modest spend on S,G&A leaving cash of £46m at the end of the half sufficient to complete the Phase 3 study, prepare for commercialisation and scale up manufacturing. Key news in the statement is an expectation that recruitment will complete in November, with data in early 2022 and that previously vaccinated patients are now included in the study. Key highlights in H1: Positive data in UK outpatient study in patients with severe symptoms; positive efficacy against variants; continued scientific support for inhaled interferon beta; and impressive management hires as the company prepares for potential near-term commercial launch. Outlook: we no longer expect revenues in 2021, and continue to base our forecasts and valuation on a major-pharma licensing deal. We now forecast higher milestones and a higher royalty rate on sales in 2022, although we see scope for Synairgen to manage 2022 commercialisation independently and capture a greater share of our forecast of $3bn in end-market sales.
vikingwarrier: I've been thinking about how this will play out over the next couple of months or three. First we need news of a succesful trial and confirmation of moving to phase 3. We already know unofficially but I think there is a delay while America puts an order together? So working on the assumption that an order and confirmation of phase 3 is about to be forthcoming next week I can see the share price reaching 500p. This will value SNG at £1bn. hardly too outlandish? The next move will be a takeover by a large pharma probably before the end of year. I have no doubt conversations have been had regarding this. My guess is £3Bn possibly more and so I can see 1500-2000p by year end. That's a pretty steep rise about to happen here.
hey fatman: Best news was SNG share price was up on v high volume. Suggests demand for the shares-which we haven't seen for a while..... Coupled with Polygon holdings TR1, what's not to like?
nicebut: I've learnt to manage expectations, especially when it comes to shares like SNG. I've been burnt too many times. Often when folk are expecting (really good) news the opposite happens or news is released that wasn't really expected that can have a detrimental effect on the share price ...Like II selling shares, BoDs selling options, being given more share options and raising money in placings...Or even general market specific news. Someone is still selling...Hence why the share price is back down at c151p..It amazes me how many times our lead share holder has changed hands over the last 14 months since I've been invested. 3 times I believe. It's also worth baring in mind that ACTIV 2 might not move to phase 3. It certainly hasn't moved swiftly or at `warp speed`, as many were hoping and predicting. So what is the reason for the delay? We don't know but the home trial might be the guide as a few have suggested....I`m quite sure that the sprinter phase 3 trial *WILL* be a success in time. However, a great deal can happen between now and those results.
nicebut: There we have it....Driven down by directors selling some of their options to pay the tax on the freebies. RNS Number : 5038I Synairgen plc 12 August 2021 Press release Synairgen plc ('Synairgen' or the 'Company') Exercise of Options and Total Voting Rights Southampton, UK - 12 August 2021: Synairgen plc (LSE: SNG), the respiratory company developing inhaled interferon beta (IFN-beta) for the treatment of severe viral lung infections, announces today that it has allotted 1,427,423 new ordinary shares of 1 pence each in the capital of the company ("Ordinary Shares") following the exercise of share options ("Option Exercise") by certain directors of the Company as set out in the table below. The options that have been exercised were due to expire in September 2021. Certain of the new ordinary shares have been sold, at a price of 140p, to meet the tax and subscription costs associated with the exercise, with the remaining shares being retained by the directors. Following the exercise and subsequent sale, the holdings of the three directors are shown below: Director New Ordinary New Ordinary Resultant Resultant % of Total Shares Shares Options Ordinary Voting Issued Sold Shares Rights Richard Marsden 538,063 296,959 2,279,513 995,771 0.49% ------------- ------------- ---------- ---------- ----------- Dr Phillip Monk 400,212 220,878 1,646,323 423,934 0.21% ------------- ------------- ---------- ---------- ----------- John Ward 489,148 269,963 1,772,958 734,092 0.36% ------------- ------------- ---------- ---------- ----------- Application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on or around the 19th August 2021. The new Ordinary Shares rank pari passu with the existing Ordinary Shares in the Company. Following the Option Exercise, the Company's issued share capital will consist of 201,341,825 Ordinary Shares. Accordingly, the figure of 201,341,825 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest
westmoreland lad: From TMS.COM 29/07/2021 Synairgen (LON:SNG), a respiratory company developing treatments for severe viral lung infections, has developed SNG001, an antiviral treatment with potential to address ‘long Covid’. The treatment boosts a naturally-occurring protein – used widely in the treatment of multiple sclerosis – that orchestrates the body’s antiviral responses. The company reported positive results from its Phase II trial of SNG001 in more than a hundred hospitalised Covid patients last summer, and further analyses, some of which have been published in The Lancet medical journal, showed that patients with significant breathlessness were three times more likely to recover when receiving SNG001. A Phase III trial began last December. Trials are underway in 12 countries, including the US where it has been granted fast track status. Initial trial results are expected in H2 this year. SNG001 can be self-administered at home, reducing strain on healthcare systems, and can be stored in concentrated form in freezers for over six years, and in ready to use format for three years. Synairgen increased spending on research and development last year by £12m, and recorded a loss from operations of £17.7m (2019: £4.8 million). But following two fundraises that brought in some £100m the company had cash of £75m at 31 December 2020 (2019: £2.5m). Synairgen’s share price began to move when the pandemic started to take hold rising from just over 6p early last year, to just under 60p by the beginning of May. When the Phase II positive results came in the price rocketed to 246p by mid-August. As with the other companies covered above it has since dropped to around 154p. But Synairgen’s promising progress towards a long Covid treatment bodes well for its long term prospects. hTTps://total-market-solutions.com/2021/07/small-cap-covid-stocks/
thelongandtheshortandthetall: For newbies looking in, to get a flavour of SNG: Synairgen plc Full Year Results 12/05/2021 7:00am UK Regulatory (RNS & others) Synairgen (LSE:SNG) Historical Stock Chart From May 2021 to Jun 2021 Click Here for more Synairgen Charts. TIDMSNG RNS Number : 3453Y Synairgen plc 12 May 2021 Press release Synairgen plc ('Synairgen' or the 'Company') Preliminary results for the year ended 31 December 2020 - Significant progress continues towards a treatment for COVID-19 Southampton, UK - 12 May 2021: Synairgen plc (LSE: SNG), the respiratory company developing inhaled interferon beta (IFN-beta) for the treatment of severe viral lung infections, today announces its preliminary statement of audited results for the year ended 31 December 2020. Highlights (including post period-end) Operational -- Positive results from Synairgen's Phase II trial (SG016) of inhaled interferon beta-1a (SNG001) in 101 hospitalised COVID-19 patients reported in July 2020 - Further analyses announced in September 2020 and trial data published in The Lancet Respiratory Medicine in November 2020 -- SG016 trial expanded to include a further 120 COVID-19 patients in the home environment - Analysis of combined data from Hospital and Home Cohorts in April 2021 showed that patients with significant breathlessness are three times more likely to recover to "no limitation of activities" on the OSCI scale when receiving SNG001 compared to placebo (p=0.004) -- SNG001 awarded Fast Track designation with IND cleared by the US FDA in December -- International Phase III trial (SG018) of SNG001 in hospitalised COVID-19 patients initiated in December 2020 - First patient dosed in January 2021, initial trial results expected in H2 2021 -- SNG001 included in US NIH government-funded ACTIV-2 Phase II/III trial in COVID-19 outpatients in January 2021 and commenced patient dosing in February 2021 - Phase II evaluation will see the recruitment of up to 220 participants -- Investment in supply chain activities for SNG001 and the Aerogen aerosol delivery system have been made in preparation for launch -- Agreements signed with Akron Biotechnology for drug substance manufacture and Catalent Biologics for fill/finish -- Positive data from interim analysis of SNG001 trial in COPD patients supporting future progression of SNG001 for exacerbating COPD patients -- Patent applications made for use of inhaled interferon beta-1a to treat: - COVID-19 patients - Virus-induced exacerbations of COPD patients undergoing treatment with systemic corticosteroids Financial -- In October 2020, Synairgen raised GBP87.1 million (before expenses) in an equity issue to fund SG018 Phase III trial, SNG001 manufacturing, regulatory activities, and to strengthen balance sheet -- In March 2020, Synairgen raised GBP14.0 million (before expenses) in an equity issue to fund initial COVID-19 clinical trial activity -- The loss from operations for the year ended 31 December 2020 was GBP17.7 million (2019: GBP4.8 million), with research and development expenditure amounting to GBP15.5 million (2019: GBP3.5 million) - GBP12.0 million year-on-year increase on research and development expenditure attributable to COVID-19 activities -- Cash balances of GBP75.0 million at 31 December 2020 (31 December 2019: GBP2.5 million) Richard Marsden, CEO of Synairgen, said: "Synairgen has made exceptional progress over 2020, with our broad-spectrum antiviral taking centre stage as a possible treatment for COVID-19, supported by a growing body of clinical evidence. Our inhaled interferon beta candidate, SNG001, has now demonstrated in a number of robust placebo-controlled clinical trials that it has the potential to prevent patient deterioration and accelerate recovery. Alongside vaccines, access to treatments that are both virus and strain agnostic is critical. Our efforts are focused on making such treatments available to the public as swiftly as possible by advancing our late-stage clinical trials, seeking marketing authorisations and ensuring the manufacturing and commercial capabilities can be rapidly up-scaled to meet potential demand."
Synairgen share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211021 03:11:17